
|Articles|July 1, 2003
Overview of Efalizumab Placebo- controlled Phase III Trials
Efalizumab is a humanized IgG monoclonal antibody directed against the alpha chain of LFA-1 (CD11a) expressed on the surface of T cells.11 Efalizumab blocks the interaction between LFA-1 and ICAM-1 on APCs, vascular endothelial cells, and cells in the dermis and epidermis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
2
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
3
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
4
Top 5 Articles of the Week: December 7-12
5


















